Qianyi Lu1, Wenjun Zou2, Bin Chen3, Chen Zou1, Minjie Zhao4, Zhi Zheng5. 1. Department of Ophthalmology, Shanghai First People's Hospital, School of Medicine, Shanghai Jiao Tong University, No. 100 Haining Road, Shanghai, 200080, China. 2. Department of Ophthalmology, Nanjing Medical University Affiliated Wuxi Second Hospital, No. 68 Zhongshan Road, Wuxi, 214002, China. 3. Department of Ophthalmology, Changshu No. 1 People's Hospital, Changshu, 215500, China. 4. Department of Ophthalmology, Nanjing Medical University Affiliated Shanghai General Hospital, Shanghai, 200080, China. 5. Department of Ophthalmology, Shanghai First People's Hospital, School of Medicine, Shanghai Jiao Tong University, No. 100 Haining Road, Shanghai, 200080, China. zzheng88@sjtu.edu.cn.
Abstract
PURPOSE: To investigate the relationship between angiopoietin-like protein 4 (ANGPTL-4) and vascular endothelial growth factor (VEGF) in the serum and vitreous of eyes in patients with proliferative diabetic retinopathy (PDR). METHODS: Thirty-five eyes of 35 patients with PDR, 20 eyes of 20 patients with non-proliferative diabetic retinopathy, 20 eyes of 20 patients with diabetes but no diabetic retinopathy, and 14 eyes of 14 nondiabetic patients with an idiopathic macular hole (IMH) were recruited from Shanghai First People's Hospital. The ANGPTL-4 and VEGF concentrations were determined using enzyme-linked immunosorbent assays. Group means were compared using one-way analysis of variance with GraphPad Prism 4.0 and SPSS ver. 17.0. The research followed the tenets of the Declaration of Helsinki. RESULTS: The ANGPTL-4 and VEGF levels were significantly higher in the vitreous and serum of patients with PDR compared with patients with IMH. There were significant correlations between the ANGPTL-4 and VEGF levels in the vitreous and serum of patients with PDR. The vitreous and serum ANGPTL-4 levels were also significantly correlated in patients with PDR. The ANGPTL-4 in both the vitreous and serum correlated with the serum triglyceride and high-density lipoprotein cholesterol levels. CONCLUSIONS: The ANGPTL-4 levels were markedly elevated and the ANGPTL-4 expression was directly correlated with the VEGF expression in the vitreous and serum of patients with PDR. The vitreous and serum ANGPTL-4 levels were also significantly correlated with serum lipids in patients with PDR. Our results suggest that the ANGPTL-4 may be used as a new therapeutic target for the treatment of PDR.
PURPOSE: To investigate the relationship between angiopoietin-like protein 4 (ANGPTL-4) and vascular endothelial growth factor (VEGF) in the serum and vitreous of eyes in patients with proliferative diabetic retinopathy (PDR). METHODS: Thirty-five eyes of 35 patients with PDR, 20 eyes of 20 patients with non-proliferative diabetic retinopathy, 20 eyes of 20 patients with diabetes but no diabetic retinopathy, and 14 eyes of 14 nondiabeticpatients with an idiopathic macular hole (IMH) were recruited from Shanghai First People's Hospital. The ANGPTL-4 and VEGF concentrations were determined using enzyme-linked immunosorbent assays. Group means were compared using one-way analysis of variance with GraphPad Prism 4.0 and SPSS ver. 17.0. The research followed the tenets of the Declaration of Helsinki. RESULTS: The ANGPTL-4 and VEGF levels were significantly higher in the vitreous and serum of patients with PDR compared with patients with IMH. There were significant correlations between the ANGPTL-4 and VEGF levels in the vitreous and serum of patients with PDR. The vitreous and serum ANGPTL-4 levels were also significantly correlated in patients with PDR. The ANGPTL-4 in both the vitreous and serum correlated with the serum triglyceride and high-density lipoprotein cholesterol levels. CONCLUSIONS: The ANGPTL-4 levels were markedly elevated and the ANGPTL-4 expression was directly correlated with the VEGF expression in the vitreous and serum of patients with PDR. The vitreous and serum ANGPTL-4 levels were also significantly correlated with serum lipids in patients with PDR. Our results suggest that the ANGPTL-4 may be used as a new therapeutic target for the treatment of PDR.
Authors: L P Aiello; T W Gardner; G L King; G Blankenship; J D Cavallerano; F L Ferris; R Klein Journal: Diabetes Care Date: 1998-01 Impact factor: 19.112
Authors: Anja Köster; Y Bernice Chao; Marian Mosior; Amy Ford; Patricia A Gonzalez-DeWhitt; John E Hale; Deshan Li; Yubin Qiu; Christopher C Fraser; Derek D Yang; Josef G Heuer; S Richard Jaskunas; Patrick Eacho Journal: Endocrinology Date: 2005-08-04 Impact factor: 4.736
Authors: Ruth B Caldwell; Manuela Bartoli; M Ali Behzadian; Azza E B El-Remessy; Mohamed Al-Shabrawey; Daniel H Platt; Gregory I Liou; R William Caldwell Journal: Curr Drug Targets Date: 2005-06 Impact factor: 3.465
Authors: L M Hermann; M Pinkerton; K Jennings; L Yang; A Grom; D Sowders; S Kersten; D P Witte; R Hirsch; S Thornton Journal: Clin Immunol Date: 2005-04 Impact factor: 3.969